Literature DB >> 21333649

Splicing factor SC35 promotes tau expression through stabilization of its mRNA.

Wei Qian1, Khalid Iqbal, Inge Grundke-Iqbal, Cheng-Xin Gong, Fei Liu.   

Abstract

Altered alternative splicing and accumulation of brain microtubule-associated protein tau are found in several tauopathies and are believed to lead to these neurodegenerative diseases. We found that in addition to promoting tau exon 10 inclusion, splicing factor SC35 also promoted tau expression in HEK-293T cells. The activity of SC35 in promotion of tau expression was limited to exon 10 containing tau isoforms. SC35 did not affect tau transcription, but stabilized tau mRNA by binding to the SC35-like element of exon 10. These results provide novel insight into the regulation of tau expression and a molecular mechanism of tauopathies.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21333649      PMCID: PMC3071244          DOI: 10.1016/j.febslet.2011.02.017

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  36 in total

Review 1.  Sorting out the complexity of SR protein functions.

Authors:  B R Graveley
Journal:  RNA       Date:  2000-09       Impact factor: 4.942

2.  Structure and novel exons of the human tau gene.

Authors:  A Andreadis; W M Brown; K S Kosik
Journal:  Biochemistry       Date:  1992-11-03       Impact factor: 3.162

3.  A transient heterochromatic state in Xist preempts X inactivation choice without RNA stabilization.

Authors:  Bryan K Sun; Aimée M Deaton; Jeannie T Lee
Journal:  Mol Cell       Date:  2006-03-03       Impact factor: 17.970

Review 4.  Tau protein as a differential biomarker of tauopathies.

Authors:  Nicolas Sergeant; André Delacourte; Luc Buée
Journal:  Biochim Biophys Acta       Date:  2005-01-03

Review 5.  Mutations causing neurodegenerative tauopathies.

Authors:  Michel Goedert; Ross Jakes
Journal:  Biochim Biophys Acta       Date:  2005-01-03

6.  Developmentally regulated expression of specific tau sequences.

Authors:  K S Kosik; L D Orecchio; S Bakalis; R L Neve
Journal:  Neuron       Date:  1989-04       Impact factor: 17.173

7.  Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.

Authors:  Erik D Roberson; Kimberly Scearce-Levie; Jorge J Palop; Fengrong Yan; Irene H Cheng; Tiffany Wu; Hilary Gerstein; Gui-Qiu Yu; Lennart Mucke
Journal:  Science       Date:  2007-05-04       Impact factor: 47.728

8.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173

9.  Repeat motifs of tau bind to the insides of microtubules in the absence of taxol.

Authors:  Santwana Kar; Juan Fan; Michael J Smith; Michel Goedert; Linda A Amos
Journal:  EMBO J       Date:  2003-01-02       Impact factor: 11.598

10.  Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain.

Authors:  M Goedert; M G Spillantini; M C Potier; J Ulrich; R A Crowther
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

View more
  9 in total

1.  Transformer 2β and miR-204 regulate apoptosis through competitive binding to 3' UTR of BCL2 mRNA.

Authors:  Y Kuwano; K Nishida; K Kajita; Y Satake; Y Akaike; K Fujita; S Kano; K Masuda; K Rokutan
Journal:  Cell Death Differ       Date:  2014-10-24       Impact factor: 15.828

2.  Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).

Authors:  Melanie McFarlane; Alasdair I MacDonald; Andrew Stevenson; Sheila V Graham
Journal:  J Virol       Date:  2015-02-25       Impact factor: 5.103

3.  Quantitative prediction of variant effects on alternative splicing in MAPT using endogenous pre-messenger RNA structure probing.

Authors:  Jayashree Kumar; Lela Lackey; Justin M Waldern; Abhishek Dey; Anthony M Mustoe; Kevin M Weeks; David H Mathews; Alain Laederach
Journal:  Elife       Date:  2022-06-13       Impact factor: 8.713

4.  Cyclic AMP-dependent protein kinase enhances SC35-promoted Tau exon 10 inclusion.

Authors:  Caoyi Chen; Nana Jin; Wei Qian; Wen Liu; Xiangling Tan; Fei Ding; Xiaosong Gu; Khalid Iqbal; Cheng-Xin Gong; Ji Zuo; Fei Liu
Journal:  Mol Neurobiol       Date:  2013-09-14       Impact factor: 5.590

5.  HIV-1-Tat Protein Inhibits SC35-mediated Tau Exon 10 Inclusion through Up-regulation of DYRK1A Kinase.

Authors:  Ferdous Kadri; Marco Pacifici; Anna Wilk; Amanda Parker-Struckhoff; Luis Del Valle; Kurt F Hauser; Pamela E Knapp; Christopher Parsons; Duane Jeansonne; Adam Lassak; Francesca Peruzzi
Journal:  J Biol Chem       Date:  2015-11-03       Impact factor: 5.157

Review 6.  Splicing factor SRSF2-centric gene regulation.

Authors:  Kun Li; Ziqiang Wang
Journal:  Int J Biol Sci       Date:  2021-04-16       Impact factor: 6.580

7.  SC35 promotes splicing of the C5-V6-C6 isoform of CD44 pre-mRNA.

Authors:  Tiing Jen Loh; Heegyum Moon; Sunghee Cho; Da-Woon Jung; Seong-Eui Hong; Do Han Kim; Michael R Green; Xuexiu Zheng; Jianhua Zhou; Haihong Shen
Journal:  Oncol Rep       Date:  2013-10-24       Impact factor: 3.906

8.  SRSF2 promotes splicing and transcription of exon 11 included isoform in Ron proto-oncogene.

Authors:  Heegyum Moon; Sunghee Cho; Tiing Jen Loh; Hyun Kyung Oh; Ha Na Jang; Jianhua Zhou; Young-Soo Kwon; D Joshua Liao; Youngsoo Jun; Soohyun Eom; Claudia Ghigna; Giuseppe Biamonti; Michael R Green; Xuexiu Zheng; Haihong Shen
Journal:  Biochim Biophys Acta       Date:  2014-09-08

9.  Decreased Expression of SRSF2 Splicing Factor Inhibits Apoptotic Pathways in Renal Cancer.

Authors:  Hanna Kędzierska; Piotr Popławski; Grażyna Hoser; Beata Rybicka; Katarzyna Rodzik; Elżbieta Sokół; Joanna Bogusławska; Zbigniew Tański; Anna Fogtman; Marta Koblowska; Agnieszka Piekiełko-Witkowska
Journal:  Int J Mol Sci       Date:  2016-09-28       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.